Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS

World News: . []

Thomas Blaettler Chief Medical Officer said Michael Benatar, MD PhD University of Miami Principal Investigator of a prior Phase II trial of arimoclomol in SOD1 ALS and Lead International Coordinating Investigator said Lucie Bruijn , PhD, ...

More news and information about Orphazyme A/S

Published By:

Globe Newswire: 13:19 GMT Friday 10th August 2018

Published: .

Search for other references to "orphazyme" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us